NASDAQ

Neuropace, Inc. (NPCE)

506 Thanks from members

NeuroPace (NPCE) demonstrates accelerating RNS System revenue growth and narrowing losses, though its premium valuation is tempered by a recent FDA regulatory setback for its IGE label expansion and lingering liquidity risks.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →